Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-76,400
Closed -$6K – 3207
2022
Q3
$6K Buy
+76,400
New +$6.47M ﹤0.01% 3197
2022
Q2
– Sell
-51,600
Closed -$6K – 3312
2022
Q1
$6K Buy
+51,600
New +$5.64M ﹤0.01% 3308
2021
Q1
– Sell
-130,800
Closed -$12K – 3378
2020
Q4
$12K Buy
+130,800
New +$11.7M ﹤0.01% 3250
2020
Q3
– Sell
-130,800
Closed -$13K – 3308
2020
Q2
$13K Hold
130,800
– – ﹤0.01% 3204
2020
Q1
$9K Hold
130,800
– – ﹤0.01% 3147
2019
Q4
$7K Buy
+130,800
New +$6.2M ﹤0.01% 3180

Other funds holding DXCM

Nuveen's DXCM Position: Q2 2026 in Review

Nuveen increased its DexCom (DXCM) stake by 6.1% in Q2 2026, buying an estimated $7.05M and bringing the position to 1,830,235 shares worth $123M. The position accounts for 0.03% of the portfolio, ranked #366.

Nuveen first reported a position in DXCM in Q4 2013 and has held it in 48 quarters since. The position peaked at $1.15B in Q3 2021. 975 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Nuveen held 1,830,235 shares of DexCom worth $123M as of Q2 2026.
  • Nuveen bought 105,768 DexCom shares in Q2 2026, an estimated $7.05M.
  • DexCom made up 0.03% of Nuveen's portfolio in Q2 2026, its #366 holding.
  • Nuveen first reported a position in DexCom in Q4 2013 and has held it in 48 quarters since.
  • Nuveen's DexCom position peaked at $1.15B in Q3 2021.
  • 975 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.